NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director. Mr. Scannell is a distinguished leader in healthcare innovation, who
NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
American Journal of Nephrology data demonstrates KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment Study (CANVAS) multinational clinical trial cohort patients NEW YORK and SALT LAKE CITY, Jan.
Seventh KidneyIntelX implementation partnership for Renalytix focused on underserved populations with high disease burden GULF COAST, Miss. and SALT LAKE CITY, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Singing River Health System and Renalytix (NASDAQ: RNLX) (LSE: RENX) today announced a partnership to
NEW YORK and SALT LAKE CITY, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that Jean M. Casner joined the Company this week on January 3, 2022 as Senior Vice President & Chief Human Resources Officer. Ms. Casner will be responsible for Renalytix’s global
NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40 th Annual J.P. Morgan Virtual Healthcare Conference.
National program establishes early care management, technology innovation and large health system engagement as a strategic priority for supporting the 34 million U.S. individuals living with diabetes ARLINGTON, Va. and SALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The American Diabetes
NEW YORK and SALT LAKE CITY, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care,
NEW YORK and SALT LAKE CITY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market open. The Company will host a corresponding conference call
Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease NEW YORK and SALT LAKE CITY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- In recognition of National Diabetes Month and concurrent with the launch of KidneyIntelX in the Veterans
